Latest News

According to exploratory biomarker analyses from the phase 3 ALINA trial, there was a benefit to disease-free survival with alectinib regardless of EML4-ALK variant among patients with NSCLC.

Results from a phase 2 study demonstrated that the addition of inhaled corticosteroids with radiotherapy significantly reduced the incidence of radiation-induced pneumonitis among patients with non-small cell lung cancer.

According to results from the phase 2 POTENTIAL study, neoadjuvant nivolumab demonstrated efficacy and safety among patients with stage I non-small cell lung cancer, at high-risk of recurrence.

According to results from the phase 2b REZILIENT1 study, zipalertinib demonstrated promising anti-tumor activity among patients with EGFR exon 20 insertion-mutated non-small cell lung cancer who experienced disease progression after treatment...

Ivonescimab showed a clinically meaningful and statistically significant improvement to progression-free survival for patients with PD-L1–positive, advanced non-small cell lung cancer, when compared with pembrolizumab.

According to phase 1/2 study results, tifcemalimab plus toripalimab showed promising antitumor activity with a manageable safety profile among patients with refractory extensive-stage small cell lung cancer.

Results from the phase 2 DURABLE trial demonstrated that durvalumab plus anlotinib in the maintenance setting improved survival results compared to durvalumab alone among patients with extensive-stage small cell lung cancer.

Pirtobrutinib treatment shows encouraging safety and activity among patients with relapsed/refractory B-cell malignancies who experience Richter transformation, according to a subgroup analysis from the phase 1/2 BRUIN study.

According to updated results from the TROPiCS-03 trial, sacituzumab govetican showed promising antitumor activity among patients with both platinum-resistant and platinum-sensitive extensive-stage small cell lung cancer in the second-line...

According to results from the phase 2 DESTINY-CRC02 trial, 5.4 mg/kg of trastuzumab deruxtecan is preferable to 6.4 mg/kg among patients with HER2-positive metastatic colorectal cancer.